47 stories
Orforglipron is Eli Lilly's small-molecule, non-peptide GLP-1 receptor agonist — the first true oral GLP-1 cleared for obesity, branded as Foundayo. Unlike semaglutide and tirzepatide, orforglipron requires no fatty-acid modification and no peptide-stabilizing matrix to survive the gut. The molecule is primarily hepatically metabolized; the label warns against use in severe hepatic impairment, but mild-to-moderate liver impairment is allowed at the standard dose.
The ACHIEVE Phase 3 program covered type-2 diabetes (ACHIEVE-1, ACHIEVE-2), obesity (ACHIEVE-3, ACHIEVE-4), and adjacent indications. The FDA approved the obesity indication in April 2026. Indirect comparisons against oral semaglutide and oral Wegovy have been mixed: orforglipron leads on HbA1c, oral semaglutide may lead on weight loss. By the April 30 Q1 2026 call, roughly 20,000 patients were on the drug, more than 8,000 prescribers had written it, and Lilly confirmed commercial access at two of the three largest US PBMs effective mid-May. On May 4, an FAERS hepatic-failure case logged April 30 surfaced publicly — Lilly's Global Patient Safety team called the event 'not reasonably related to Foundayo,' and the company released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program.
The small-molecule approach carries pricing and manufacturing implications the peptide GLP-1 economy does not — CDMO capacity stops being the bottleneck, and small-molecule generics will eventually follow a different cost curve. Stories here cover trial readouts, post-launch tracking, and competing oral programs.
Eli Lilly's Foundayo (orforglipron) won FDA approval with aggressive pricing as low as $25/month with savings card. Medicare Part D coverage could bring costs to $50/month starting July 2026.
Orforglipron (Foundayo) is the first GLP-1 pill that can be taken at any time without food or water restrictions, a major differentiator from oral semaglutide which requires morning dosing on an empty stomach.
Published the day after Foundayo's FDA approval, a new indirect comparison found oral semaglutide may produce greater weight loss than orforglipron with fewer GI discontinuations.
Managed Healthcare Executive compares Foundayo (orforglipron) vs oral Wegovy (semaglutide). ACHIEVE-3 trial data showed Foundayo superior on HbA1c, but oral Wegovy may edge ahead on weight loss.
In-depth comparison of Foundayo against existing GLP-1 drugs, noting 27 lbs average weight loss over 72 weeks at the highest dose. Experts hope more oral options will drive down costs and offer patients greater flexibility versus injectable regimens.
Foundayo became the first new molecular entity cleared under the Commissioner's National Priority Voucher Program, with review completed 294 days before the PDUFA date. Commercial pricing set at $25/month insured and $149/month self-pay at the lowest dose.
The FDA approved Foundayo, a once-daily oral GLP-1 pill that can be taken any time without food or water restrictions. In trials, patients lost an average of 11% body weight over one year. It was approved under the FDA's National Priority Voucher program.
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
Eli Lilly's oral GLP-1 drug orforglipron is among the most consequential FDA decisions in Q2 2026. Analysts expect it to help Lilly's tirzepatide franchise exceed $100 billion in peak revenue.
Pharmacy Times covers orforglipron's ability to cut A1C and drive meaningful weight loss with easier dosing than injections, potentially reshaping the GLP-1 treatment landscape.
Eli Lilly's oral orforglipron demonstrated superior HbA1c reduction and weight loss vs oral semaglutide in Phase 3, strengthening the case ahead of an April FDA decision.